Specialized Data Analytics for Infusion Businesses
The payer dynamics, authorization requirements, drug economics, and revenue cycle patterns in infusion and specialty pharmacy organizations are specific to this space. SolisRx offers specialized data analytics and infrastructure services for each segment.
4.8/5
610+ Reviews
Why Industry-Appropriate Solutions Matters
Most analytics platforms are built for healthcare broadly. They handle the billing and surface the denials. They don't reveal why CARC 16 denials spiked at two sites after a Commercial plan quietly updated its IVIG documentation requirements, or tell a home infusion CFO which authorization windows are expiring this week across their full patient census ranked by dollar value at risk.
The depth of analysis that matters in infusion is only possible when the analyst understands infusion. SolisRx works exclusively in this space, so you can scale each peak of the Data Maturity Mountain confidently, driving revenue and margin, and taking advantage of the growth momentum in the infusion space.
The depth of analysis that matters in infusion is only possible when the analyst understands infusion. SolisRx works exclusively in this space, so you can scale each peak of the Data Maturity Mountain confidently, driving revenue and margin, and taking advantage of the growth momentum in the infusion space.
Ambulatory Infusion Centers
Multi-site ambulatory infusion is an analytically complex business. Revenue is driven by a combination of therapy mix, payer contract performance, referral volume, and operational execution. Each of these varies across locations and interacts with the others in ways that aggregate reporting can’t surface.
Financial stakes in infusion businesses are unusually concentrated. A relatively small number of high-margin patients (on IVIG, specialty biologics, or enzyme replacement therapies) can disproportionately impact total profit. Denials are large and difficult to recover, though often easier to prevent.
The organizations SolisRx works with most frequently are regional and national ambulatory infusion platforms: 4 to 50+ locations, often growing faster than their internal analytics infrastructure can support.
Financial stakes in infusion businesses are unusually concentrated. A relatively small number of high-margin patients (on IVIG, specialty biologics, or enzyme replacement therapies) can disproportionately impact total profit. Denials are large and difficult to recover, though often easier to prevent.
The organizations SolisRx works with most frequently are regional and national ambulatory infusion platforms: 4 to 50+ locations, often growing faster than their internal analytics infrastructure can support.
Common starting questions: Why is Site 4 underperforming against the rest of the business? Which payer is driving our denial rate up? Are we ready for what a buyer will find?
View Details
Home Infusion Providers
Home infusion combines the revenue cycle complexity of infusion billing with the logistics complexity of a distributed care model. Therapy is delivered in patients’ homes across a geography, which means billing, nursing scheduling, authorization tracking, and supply chain are all running simultaneously against a patient census that may number in the hundreds.
Home infusion providers face additional RCM complexity with decisions around specifying Part B (Medical) benefit or Part D (Pharmacy) benefit, or administering medication as IV versus subcutaneous (SQ) injection based on patient access and financial factors.
Home infusion providers face additional RCM complexity with decisions around specifying Part B (Medical) benefit or Part D (Pharmacy) benefit, or administering medication as IV versus subcutaneous (SQ) injection based on patient access and financial factors.
Common starting questions: Which authorizations are expiring this week? Where is our IVIG denial rate coming from? How do we track the full referral-to-treatment pipeline across a distributed caseload?
View Details
Specialty Pharmacies
Specialty pharmacies are analytically distinct from other healthcare businesses. The dispensing transaction and the reimbursement event are often separated by payer adjudication processes that create denial, reversal, and recoupment patterns unique to the specialty drug channel. Hub services, limited distribution networks, prior authorization workflows, and the interaction between medical benefit and pharmacy benefit create a revenue cycle environment where errors concentrate at the intersections.
The organizations SolisRx works with range from independent specialty pharmacies to infusion-adjacent hybrid models that dispense and also coordinate care. Common analytical priorities include therapy mix and margin visibility, payer performance by drug category, prior authorization and appeals analytics, and the operational reporting that supports LDD and hub contracting relationships.
The organizations SolisRx works with range from independent specialty pharmacies to infusion-adjacent hybrid models that dispense and also coordinate care. Common analytical priorities include therapy mix and margin visibility, payer performance by drug category, prior authorization and appeals analytics, and the operational reporting that supports LDD and hub contracting relationships.
Common starting questions: Where is our dispensing revenue leaking? How do our payer-specific denial rates compare by therapy category? What does our data look like for a hub services or LDD negotiation?
View Details
Specialty Care Providers
Specialty care practices like rheumatology, behavioral health, and medication-assisted treatment clinics face many of the same revenue cycle challenges as infusion centers because they administer the same infused and injectable therapies. Buy-and-bill drug economics, prior authorization requirements for specialty biologics, and CARC code concentration in denial patterns are infusion-billing problems, and they follow the drug wherever it’s administered.
The difference for specialty care practices is that these challenges sit alongside the specialty care delivery model, rather than being the core business. That means the analytics infrastructure to manage infusion-related revenue cycle performance rarely gets built internally, and the revenue leakage goes undetected longer.
The difference for specialty care practices is that these challenges sit alongside the specialty care delivery model, rather than being the core business. That means the analytics infrastructure to manage infusion-related revenue cycle performance rarely gets built internally, and the revenue leakage goes undetected longer.
Are we capturing everything we’re entitled to on our in-office infusion and injection programs? Where are our biologic prior authorizations failing? What’s our contribution margin on infused therapy versus oral?
